1. Introduction {#sec1}
===============

Renal cell carcinoma (RCC) is the most common cancer originating from the kidney \[[@B1]\]. Lungs, bones, liver, and brain are the most common sites of RCC metastasis \[[@B2], [@B3]\]. Uncommon metastatic sites, including the gastrointestinal tract \[[@B2]--[@B4]\], have also been reported. Gastric metastasis from RCC is rare \[[@B5], [@B6]\]. Gastric metastases are typically asymptomatic, single, and located in the gastric body or fundus \[[@B5], [@B6]\]. If they are symptomatic, then gastrointestinal bleeding and anemia are the most common presentations \[[@B5], [@B6]\]. RCC has the potential for late solitary metastasis. Isolated gastric metastasis from RCC can occur up to 20 years after radical nephrectomy \[[@B7]\]. Immunohistochemistry is useful and increasingly utilized in the diagnosis of RCC \[[@B8], [@B9]\]. The prognosis in patients with metastatic RCC is generally poor, with a five-year survival rate of 5--30% \[[@B10]\]. Treatment options include embolization and epinephrine injection for bleeding and endoscopic resection or surgery \[[@B11]--[@B16]\]. Surgical resection remains the best therapeutic option for a solitary gastric metastasis, resulting in significant survival prolongation in eligible patients \[[@B8]\].

2. Case Summary {#sec2}
===============

A 67-year-old man presented with multiple episodes of melena. His past medical history involved polycystic kidney disease, live donor renal transplantation in 2002 with chronic immunosuppression, and metastatic left-sided RCC that had been treated with radical nephrectomy and the resection of a pulmonary metastasis in 2014. The patient had chronic kidney disease, stage 3, and a recent ST segment elevation myocardial infarction with percutaneous coronary intervention and drug eluting stent insertion. The patient was on 81 mg of aspirin daily and 90 mg of ticagrelor twice daily.

His vital signs on presentation were blood pressure of 121/82 mmHg, pulse of 105 bpm, and oral temperature of 97.7°F (36.5 C). On physical examination, the patient was pale and in mild distress. Abdominal and cardiopulmonary exams were unremarkable. Initial laboratory evaluation included a hemoglobin (Hb) level of 8.8 g/dl (normal: 13.5--17.5 g/dl), white blood cell (WBC) count of 11,300/cmm (normal: 4,000--11,000/cmm), platelet count of 344,000 cmm (normal: 150,000--450,000/cmm), serum creatinine level of 2.3 mg/dl (normal: 0.9--1.2 mg/dl), aspartate aminotransferase level of 27 units/L (normal: 15--46 units/L), alanine aminotransferase level of 14 units/L (normal: 13--69 units/L), alkaline phosphatase level of 117 units/L (normal: 42--140 units/L), and international normalized ratio of 1.2. The patient was admitted for stabilization and further evaluation of gastrointestinal bleeding.

The patient was intravenously given 80 mg pantoprazole, followed by 8 mg/hour continuous infusion. A total of 2 units of packed red blood cells were transfused. Aspirin and ticagrelor were initially held. On hospitalization day 1, the patient was hemodynamically stable and his Hb level increased to 9.9 g/dl after transfusion. The gastroenterology service proceeded with esophagogastroduodenoscopy (EGD). The EGD ([Figure 1](#fig1){ref-type="fig"}) showed a 2.5 to 3.0 cm polypoid mass in the gastric fundus. The polyp was completely removed with a polypectomy snare and cautery. Bleeding occurred after polyp removal, and hemostasis was achieved via local epinephrine injection and the application of two Cook hemostasis clips.

The histological examination ([Figure 2](#fig2){ref-type="fig"}) demonstrated a submucosal tumor comprising nests and fascicles of cells with abundant clear cytoplasm and moderately pleomorphic nuclei with prominent eosinophilic nucleoli. A background vascular network and acute and chronic inflammation were observed. Immunohistochemical staining ([Figure 3](#fig3){ref-type="fig"}) was positive for pan-keratin PAX2 and PAX8. Both the morphology and immune phenotypes were most consistent with metastatic clear cell RCC, comparable with the right lung lesion resected in 2014.

The patient was observed overnight in the intensive care unit. His Hb levels were unchanged, and he remained hemodynamically stable. Aspirin and ticagrelor treatments were resumed. The oncology service decided to follow him as an outpatient. Chemotherapy was not initiated with his recent gastrointestinal blood loss and myocardial infarction. He is following up now with the oncology and cardiology clinics and has been doing well about 1 year after his presentation.

3. Discussion {#sec3}
=============

RCC is the most common cancer originating from the kidney. This cancer is responsible for 80 to 85% of all primary renal neoplasms and accounts for 3% of all adult malignancies \[[@B1]\]. RCC has an abundant blood supply and can metastasize to any organ \[[@B2], [@B3]\]. The most common sites of metastasis include the lungs, bones, liver, and brain \[[@B2], [@B3]\]. However, RCCs can also metastasize to unusual sites, including the pancreas, thyroid gland, adrenal gland, skeletal muscle, and skin \[[@B4]\]. Studies have reported that a metastasis is detected in approximately 30% of RCC patients on initial presentation \[[@B3]\].

Gastric metastases from RCC are exceedingly rare \[[@B5], [@B6]\]. Pollheimer et al. \[[@B5]\] reported 5 patients who developed gastric metastases from an Austrian database of 2,082 RCC patients. In one instance, an isolated gastric metastasis from RCC was reported 20 years after radical nephrectomy \[[@B7]\]. [Table 1](#tab1){ref-type="table"} summarizes the reported cases of gastric metastases from RCC in English literature.

Most RCC gastric metastases are located in the gastric body and fundus. Single tumors predominate over multiple tumors \[[@B6]\]. Histologically, these metastases are situated in the submucosa \[[@B3], [@B12]\]. Clear cell histology is the predominant form of RCC. The presence of clear cell morphology in any unknown lesion should prompt the pathologist to consider the possibility of metastatic RCC, even in the absence of a prior diagnosis \[[@B17]\]. Endoscopically, the metastasis typically appears as a polypoid submucosal-like tumor with a central depression.

In general, the outcome with metastatic RCC is poor with 5-year survival rates of 5--30% \[[@B10]\]. Patients with a single metastasis fare better than those with multiple metastases.

Immunohistochemistry, particularly for vimentin and PAX-2, is a useful adjunct in the diagnosis of RCC \[[@B8], [@B9]\]. Vimentin is an intermediate filament protein expressed in normal renal tissues \[[@B8]\], and PAX-2 is a transcription factor required for the development and proliferation of renal tubules \[[@B9]\]. Both proteins are expressed in 85% of metastatic clear cell RCCs \[[@B8], [@B9]\].
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![EGD showing a 2.5 to 3.0 cm polypoid mass in the gastric fundus.](CRIGM2017-5879374.001){#fig1}

![Histological evaluation including H&E staining, showing a tumor comprising nests and fascicles of cells with abundant clear cytoplasm and moderately pleomorphic nuclei with prominent eosinophilic nucleoli.](CRIGM2017-5879374.002){#fig2}

![Positive immunohistochemical staining for PAX-2, consistent with clear cell RCC.](CRIGM2017-5879374.003){#fig3}

###### 

Reported cases of gastric metastases from RCC in English literature.

  Case and reference                      Age (years), sex   Gastrointestinal symptoms           Location                     Gross appearance                      Histology       Treatment
  --------------------------------------- ------------------ ----------------------------------- ---------------------------- ------------------------------------- --------------- -------------------------------------------------------
  Sullivan et al. 1980 \[[@B18]\]         69, male           Bleeding                            Antrum                       Mass, single                          Not specified   Antrectomy
  Boruchowicz et al. 1995 \[[@B19]\]      48, male           Dysphagia                           Fundus                       Polypoid, single                      Clear cell      Chemotherapy
  Blake et al. 1995 \[[@B11]\]            63, male           Bleeding                            Not specified                Not specified                         Not specified   Embolization
  Odori et al. 1998 \[[@B20]\]            58, male           Not specified                       Not specified                Ulcerated, single                     Clear cell      Total gastrectomy with regional lymph node dissection
  Picchio et al. 2000 \[[@B12]\]          64, female         Bleeding                            Body                         Polyp, single                         Clear cell      Subtotal gastrectomy
  Mascarenhas et al. 2001 \[[@B21]\]      66, male           Bleeding                            Body                         Ulcerated, single                     Clear cell      Partial gastrectomy
  Kobayashi et al. 2004 \[[@B22]\]        78, male           Anemia                              Lower one-third of stomach   Mass, single                          Not specified   Gastrectomy
  Kok Wee et al. 2004 \[[@B7]\]           60, male           Bleeding                            Body                         2 lesions, protruding and ulcerated   Clear cell      Endoscopic therapy
  Lamb et al. 2005 \[[@B13]\]             69, male           Bleeding                            Body                         Mass, single                          Clear cell      Embolization, octreotide
  Riviello et al. 2006 \[[@B23]\]         68, male           Bleeding                            Fundus                       Mass, single                          Clear cell      Total gastrectomy, chemotherapy
  Pezzoli et al. 2007 \[[@B15]\]          78, male           Anemia                              Body                         Polyps, multiple                      Clear cell      Endoscopic mucosal resection
  Saidi and Remine 2007 \[[@B24]\]        Not specified      Bleeding                            Body                         Polyp, single                         Clear cell      Wedge resection
  Pollheimer et al. 2008 \[[@B5]\]        69, male           Epigastric pain, Nausea, vomiting   Body                         Mass, single                          Clear cell      Tamoxifen
  Pollheimer et al. 2008 \[[@B5]\]        77, male           No symptoms                         Antrum                       Ulcerated, single                     Clear cell      Interferon
  Pollheimer et al. 2008 \[[@B5]\]        83, female         Bleeding                            Antrum                       Mass, multiple                        Clear cell      Endoscopic therapy, interferon
  Pollheimer et al. 2008 \[[@B5]\]        65, female         Bleeding                            Not specified                Multiple                              Clear cell      Endoscopic therapy
  Pollheimer et al. 2008 \[[@B5]\]        69, male           Anemia, epigastric pain             Body                         Multiple                              Clear cell      Endoscopic therapy, sunitinib
  Kibria et al. 2009 \[[@B25]\]           53, male           Bleeding                            Fundus                       Polypoid, single                      Clear cell      None
  Yamamoto et al. 2009 \[[@B8]\]          74, male           Bleeding                            Body                         Polypoid, single                      Not specified   Wedge resection
  Tiwari et al. 2010 \[[@B26]\]           58, female         Bleeding                            Antrum                       Polypoid, single                      Clear cell      Subtotal gastrectomy
  García-Campelo et al. 2010 \[[@B27]\]   75, male           No symptoms                         Fundus and body              Polypoid, multiple                    Not specified   Sunitinib
  Sugasawa et al. 2010 \[[@B28]\]         69, male           Anemia                              Fundus                       Ulcerated, single                     Clear cell      Wedge resection
  Eslick and Kalantar 2011 \[[@B29]\]     65, male           Bleeding                            Lower stomach                Polypoid, single                      Clear cell      Polypectomy
  Kim et al. 2012 \[[@B30]\]              79, male           Abdominal pain                      Body                         Erosive, single                       Clear cell      Partial gastrectomy
  Xu et al. 2012 \[[@B17]\]               60, male           Anemia                              Body                         Polyp, multiple                       Clear cell      Polypectomy, sunitinib, sorafenib
  Siriwardana et al. 2012 \[[@B31]\]      71, male           Anemia                              Not specified                Polypoid, single                      Clear cell      Endoscopic mucosal resection
  Namikawa et al. 2012 \[[@B32]\]         65, male           Not specified                       Body                         Polypoid, single                      Clear cell      Wedge resection
  Rodrigues et al. 2012 \[[@B33]\]        45, female         Bleeding                            Body                         Ulcerated, single                     Not specified   Sunitinib
  Chibbar et al. 2013 \[[@B34]\]          69, female         Anemia                              Body                         Polypoid, single                      Clear cell      Endoscopic mucosal resection
  Rita et al. 2014 \[[@B6]\]              77, male           Bleeding, abdominal pain            Body                         Polypoid, single                      Clear cell      Endoscopic resection
  Greenwald et al. 2014 \[[@B35]\]        62, male           No symptoms                         Fundus                       Mass, single                          Clear cell      Partial gastrectomy
  Costa et al. 2014 \[[@B36]\]            66, female         Anemia                              Body                         Ulcerated, single                     Not specified   Laparoscopic wedge resection
  Kumcu et al. 2014 \[[@B37]\]            59, male           Bleeding, weight loss               Body                         Polypoid, single                      Clear cell      Partial gastrectomy
  Sakurai et al. 2014 \[[@B38]\]          62, male           Bleeding, anemia                    Body                         Mass, single                          Clear cell      Partial gastrectomy
  Forman et al. 2015 \[[@B39]\]           76, female         Bleeding, anemia                    Cardia                       Mass, single                          Clear cell      Not specified
  Kongnyuy et al. 2016 \[[@B40]\]         68, male           Anemia, bleeding                    Fundus                       Mass, single                          Clear cell      Not specified
  Our case 2016                           67, male           Bleeding                            Fundus                       Polypoid, single                      Clear cell      Polypectomy, plan for chemotherapy
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